Navigation
Hair Loss News Archives
March 2006
Procter investing in hair-raising program
March 2006
Procter & Gamble Co., known for its Pantene and Head & Shoulders shampoos, is
now exploring ways to stop baldness, investing $1 million in a company that is
developing a topical drug for hair loss.
The investment, in Curis Inc., comes after the company achieved its first
preclinical milestone in a hair-growth program with Procter's pharmaceutical
unit.
If Curis reaches the second milestone, Procter (NYSE: PG - News) will pay
the company as much as $1.8 million more, according to wire reports.
The program is dedicated to the development of a drug for hair-growth disorders,
such as male-pattern baldness and female-pattern hair loss. The drug will be
applied directly to the skin.
Under the development agreement, Curis has retained an option to co-develop the
product through phase II clinical trials. Curis also has options on veterinary
uses, of which Procter has the first rights to a commercial agreement.
Curis (Nasdaq: CRIS - News) based in Cambridge, Mass., is a therapeutic drug
development company exploring treatments for cancer, neurological disorders,
hair growth and kidney disease. Procter, based in Cincinnati, is the world's
largest consumer products maker.